Navigation Links
New Study Predicts Yield for Biofuel Jatropha
Date:7/1/2010

Champaign, IL- An article in the current issue of Global Change Biology Bioenergy predicts the yield of the biofuel crop, Jatropha curcas L., for present and future climates.

Researchers related reproductive potential with the natural occurrence of Jatropha, with biogeographic modeling and ecological principles. This model allowed them to estimate yield response to climate factors and map worldwide productivity for present and future climates.

They used a novel fitness-based modeling approach because agroclimatic and physiological data on Jatropha is limited.

In their article, "Global mapping of Jatropha curcas yield based on response of fitness to present and future climate," Antonio Trabucco and colleagues point out that Jatropha grows in a wide range of climatic conditions, including tropical and subtropical areas with limited suitability for intensive cropping.

Jatropha requires higher annual precipitation to achieve significant biofuel production than previously thought. In addition, the study shows that climate changes over the next decade will lead to decreased yields in zones with reduced precipitation and increased yields in regions with reduced frost risks.


'/>"/>

Contact: Antonio Trabucco
Antonio.Trabucco@ees.kuleuven.be
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related biology news :

1. Study suggests more fish than thought may thrive in the oceans depths
2. Flowering and freezing tolerance linked in wheat, study shows
3. Apples grow larger when cells dont divide, study shows
4. Study shows stability and utility of floating wind turbines
5. Arctic climate may be more sensitive to warming than thought, says new study
6. Study challenges long-held assumption about competition in disturbed ecosystems
7. Introducing Robofish: Leading the crowd in studying group dynamics
8. International study identifies 12 new genetic risk factors for type 2 diabetes
9. Same types of cell respond differently to stimulus, Stanford study shows
10. Soil-borne pathogens drive tree diversity in forests, study shows
11. Organic pesticides not always greener choice, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: